Mohamed E Abouelela
Overview
Explore the profile of Mohamed E Abouelela including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
107
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Khayat E, Abouelela M, Abdelhamid R, Alorainy M, Shaaban K
Bull Pharm Sci
. 2025 Feb;
47(1):151-168.
PMID: 39902252
Background: The pandemic of COVID-19 has stressed the exaggerated demand for innovative treatments, prompting the search for new sources. Plant endophytic fungi produce a diverse array of biologically active compounds,...
2.
Abdelrahem M, Abouelela M, Abo-Dahab N, Hassane A
AIMS Microbiol
. 2024 Dec;
10(4):1024-1051.
PMID: 39628715
Fungal co-culture is a method that allows the detection of interactions between fungi, enabling the examination of bioactive novel metabolites induction that may not be produced in monocultures. Worldwide, basal...
3.
Al Mousa A, Abouelela M, Mansour A, Nasr M, Ali Y, Al Ghamidi N, et al.
Curr Issues Mol Biol
. 2024 Oct;
46(10):11681-11699.
PMID: 39451574
Burn injuries, which significantly affect global public health, require effective treatment strategies tailored to varying severity. Fungi are considered a sustainable, easily propagated source for lead therapeutic discovery. In this...
4.
Hassane A, Eldiehy K, Saha D, Mohamed H, Mosa M, Abouelela M, et al.
Arch Microbiol
. 2024 Jul;
206(7):338.
PMID: 38955856
Oleaginous fungi have attracted a great deal of interest for their potency to accumulate high amounts of lipids (more than 20% of biomass dry weight) and polyunsaturated fatty acids (PUFAs),...
5.
Abouelela M, Helmy Y
Microorganisms
. 2024 Mar;
12(3).
PMID: 38543481
Next-generation probiotics (NGPs) represent an innovative group of beneficial bacteria that are currently undergoing research and development. NGPs are designed not only for conventional use as foods or dietary supplements...
6.
Orabi M, Abouelela M, Darwish F, Abdelkader M, Elsadek B, Abdullah Al Awadh A, et al.
Front Pharmacol
. 2024 Feb;
15:1337910.
PMID: 38370475
Hepatocellular carcinoma (HCC) is a prevalent cancer worldwide. Late-stage detection, ineffective treatments, and tumor recurrence contribute to the low survival rate of the HCC. Conventional chemotherapeutic drugs, like doxorubicin (DOX),...
7.
Abdullah Al Awadh A, Sakagami H, Amano S, Sayed A, Abouelela M, Alhasaniah A, et al.
Front Pharmacol
. 2024 Feb;
15:1325272.
PMID: 38303989
Oral cancer is a severe health problem that accounts for an alarmingly high number of fatalities worldwide. (L.) Dunal has been extensively studied against various tumor cell lines from different...
8.
Al Mousa A, Abouelela M, Al Ghamidi N, Abo-Dahab Y, Mohamed H, Abo-Dahab N, et al.
Curr Issues Mol Biol
. 2024 Jan;
46(1):221-243.
PMID: 38248318
and are recognized as causative agents in numerous diseases, and the rise of multidrug-resistant strains emphasizes the need to explore natural sources, such as fungi, for effective antimicrobial agents. This...
9.
Orabi M, Alshahrani M, Sayed A, Abouelela M, Shaaban K, Abdel-Sattar E
Metabolites
. 2023 Jan;
13(1).
PMID: 36677018
Leishmaniasis is a group of infectious diseases caused by protozoa. The ineffectiveness, high toxicity, and/or parasite resistance of the currently available antileishmanial drugs has created an urgent need for safe...
10.
Orabi M, Alqahtani O, Alyami B, Abdullah Al Awadh A, Abdel-Sattar E, Matsunami K, et al.
Pharmaceuticals (Basel)
. 2022 Dec;
15(12).
PMID: 36559012
Lung cancer and cutaneous leishmaniasis are critical diseases with a relatively higher incidence in developing countries. In this research, the activity of leaf hydromethanolic extract and its solvent-fractions (-hexane, EtOAc,...